Progress toward poliomyelitis eradication — January 2023–December 2024
Archives of Public Health·
- DOI
- 10.1186/s13690-026-02047-2
- PMID
- —
- PMCID
- —
- OpenAlex
- —
- Study type
- Journal article
- Publisher
- Springer Science and Business Media LLC
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The findings highlight the continued risk posed by persistent WPV1 transmission in endemic areas and the geographic spread of cVDPVs, informing the need for improved campaign quality, sustained surveillance, expanded nOPV2 use where cVDPV2 transmission persists, and strategic resource allocation under declining global health funding.
Structured evidence summary
Research question
The report summarizes global polio immunization activities, surveillance performance, and the epidemiology of poliovirus transmission during January 2023–December 2024, framed against the GPEI's extended 2029 eradication target.
Study design
A descriptive global surveillance and epidemiologic report drawing on WHO Polio Information System (POLIS) surveillance and virologic data and WHO/UNICEF immunization coverage estimates, with standardized AFP and environmental surveillance criteria used to define cVDPV outbreaks.
Population and setting
Global scope, with endemic transmission focused in Afghanistan and Pakistan and cVDPV detections reported across Africa, Southeast Asia, the Middle East, and Europe.
Main findings
WPV1 cases rose from 12 cases in 3 provinces in 2023 to 99 cases in 10 provinces in 2024, reported only by Afghanistan and Pakistan. Reported cVDPV cases declined 12% from 529 in 2023 to 464 in 2024, yet cVDPV detections expanded geographically to 40 countries in 2024, including 14 countries with no detections in 2023.
Public-health relevance
The findings highlight the continued risk posed by persistent WPV1 transmission in endemic areas and the geographic spread of cVDPVs, informing the need for improved campaign quality, sustained surveillance, expanded nOPV2 use where cVDPV2 transmission persists, and strategic resource allocation under declining global health funding.
Important limitations
The summary relies solely on the supplied single-article abstract and bibliographic metadata; no author-stated limitations were available in the abstract, so decision-grade interpretation requires review of the original paper.
GIDS interpretation
This article is discoverable within GIDS disease areas for poliomyelitis and acute flaccid paralysis and tagged to surveillance and vaccination topics; it provides historical epidemiologic context but should not be interpreted as confirmation of any current surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.